What is Seraxis?
Founded in 2013, Seraxis operates at the intersection of advanced cell biology and medical device engineering. The company's primary value proposition lies in its proprietary cell line technology, which enables the large-scale production of human pancreatic islets. Complementing this biological innovation is SeraGraft, a specialized device designed to protect these transplanted cells from immune system rejection. This dual-pronged approach addresses the fundamental challenges of long-term diabetes management, moving beyond traditional insulin therapy toward a potential functional cure. By maintaining a focus on both the therapeutic agent and the protective delivery mechanism, Seraxis occupies a unique niche in the biopharmaceutical sector, attracting interest from both strategic corporate partners and specialized venture capital firms.
How much funding has Seraxis raised?
Seraxis has raised a total of $40.1M across 2 funding rounds:
Debt
$87K
Series C
$40M
Debt (2021): $87K with participation from PPP
Series C (2021): $40M led by Frazier Healthcare Partners, Eli Lilly and Company, Polaris Partners, and JDRF T1D Fund
Key Investors in Seraxis
Frazier Healthcare Partners
A late clinical-stage biopharmaceutical investor focused on developing and commercializing new treatments for gastrointestinal disorders and other high-need medical areas.
Eli Lilly and Company
A global biopharmaceutical leader with a deep-rooted commitment to diabetes research, oncology, and immunology, leveraging extensive R&D resources to drive medical innovation.
Polaris Partners
A venture capital firm specializing in transformational biotech and healthcare companies, providing strategic coaching and operational resources to foster long-term growth.
What's next for Seraxis?
With the recent capital infusion, Seraxis is expected to prioritize the clinical advancement of its lead programs. The strategic focus will likely center on optimizing the manufacturing processes for its pancreatic islets and conducting rigorous testing of the SeraGraft device to ensure long-term efficacy and safety. As the company moves forward, the integration of these technologies into clinical practice remains the primary objective. The involvement of high-profile investors suggests a clear path toward regulatory milestones and potential commercialization. Future growth will depend on the company's ability to maintain its technological edge while navigating the complex regulatory environment governing cell-based therapies and medical devices.
See full Seraxis company page
